Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has upgraded ProQR Therapeutics from Neutral to Buy and set a price target of $2.
November 08, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProQR Therapeutics has been upgraded from Neutral to Buy by Chardan Capital, with a new price target of $2.
The upgrade from Neutral to Buy by Chardan Capital indicates a positive outlook for ProQR Therapeutics. The new price target of $2 also suggests potential upside for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100